RESUMO
OBJECTIVE: To explore the clinicopathological correlation between CD4(+) T lymphocyte count and superficial lymphadenopathy HIV/AIDS patients. METHODS: A total of 1066 HIV/AIDS patients were included in this study. The incidence of superficial lymphadenopathy, peripheral blood CD4(+) T lymphocyte counts and histological features of superficial lymphadenopathy were analyzed. RESULTS: Among 1066 patients, 126 cases (11.8%) presented with superficial lymphadenopathy. Of the 126 cases, there were 69 cases with CD4(+) T lymphocyte counts < 100/µl and clinical diagnoses including tuberculosis (37 cases), reactive hyperplasia (8 cases), AIDS-related lymphadenopathy (18 cases), penicillium diseases (12 cases), fungal infection (5 cases) and non-tuberculous mycobacterial infection (1 case). Twenty-six cases had CD4(+) T lymphocyte counts between 100/µl to 200/µl and clinical diagnosis including tuberculosis (12 cases), reactive hyperplasia (8 cases), AIDS-related lymphadenopathy(6 cases), penicillium disease (2 cases) and non-Hodgkin lymphoma (1 case). Twenty-nine cases had CD4(+) T lymphocyte counts > 200/µl and clinical diagnoses including tuberculosis (11 cases), reactive hyperplasia (12 cases), AIDS-related lymphadenopathy (3 cases), Penicillium diseases (1 case) and non-Hodgkin lymphoma (4 cases). The CD4(+) T lymphocyte counts among patients with tuberculosis, AIDS-related lymphadenopathy and Penicillium diseases were significantly different (χ(2) = 8.861, P = 0.012). A significant correlation between the incidence of superficial lymphadenopathy and CD4(+) T lymphocyte counts was found (χ(2) = 375.41, P = 0.000). CONCLUSIONS: The most common cause of superficial lymphadenopathy in HIV/AIDS patients is tuberculosis, followed by lymph node reactive hyperplasia, AIDS-related lymphadenopathy and Penicillium disease. Low CD4(+) T lymphocyte count correlates with an increased incidence of superficial lymphadenopathy and the risk of opportunity infection. Therefore, determination of peripheral blood CD4(+) T lymphocyte count should become an integral marker for the early diagnosis and treatment of superficial lymphadenopathy in HIV/AIDS patients.
Assuntos
Complexo Relacionado com a AIDS/sangue , Síndrome da Imunodeficiência Adquirida/sangue , Contagem de Linfócito CD4 , Infecções por HIV/sangue , Complexo Relacionado com a AIDS/complicações , Complexo Relacionado com a AIDS/patologia , Infecções Oportunistas Relacionadas com a AIDS/sangue , Infecções Oportunistas Relacionadas com a AIDS/complicações , Infecções Oportunistas Relacionadas com a AIDS/patologia , Síndrome da Imunodeficiência Adquirida/complicações , Síndrome da Imunodeficiência Adquirida/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Infecções por HIV/complicações , Infecções por HIV/patologia , Humanos , Linfonodos/patologia , Masculino , Pessoa de Meia-Idade , Tuberculose/sangue , Tuberculose/complicações , Tuberculose/patologia , Adulto JovemRESUMO
BACKGROUND: Most methods for estimation of rates of RNA production are not applicable in human in vivo clinical studies. We describe here an approach for measuring ribosomal RNA turnover in vivo using [6,6-(2)H(2)]-glucose as a precursor for de novo RNA synthesis. Because this method involves neither radioactivity nor toxic metabolites, it is suitable for human studies. METHODS: For method development in vitro, a lymphocyte cell line (PM1) was cultured in the presence of [6,6-(2)H(2)]-glucose. RNA was extracted, hydrolyzed enzymatically to ribonucleosides, and derivatized to either the aldonitrile tetra-acetate or the pentafluoro triacetate derivative of the pentose before GC-MS. We identified optimum derivatization and analysis conditions and demonstrated quantitative incorporation of deuterium from glucose into RNA of dividing cells. RESULTS: Pilot clinical studies demonstrated the applicability of this approach to blood leukocytes and solid tissues. A patient with chronic lymphocytic leukemia received [6,6-(2)H(2)]-glucose (1 g/kg) orally in aliquots administered every 30 min for a period of 10 h. When we analyzed CD3(-) B cells that had been purified by gradient centrifugation and magnetic-bead adhesion, we observed deuterium enrichment, a finding consistent with a ribosomal RNA production rate of about 7%/day, despite the slow division rates observed in concurrent DNA-labeling analysis. Similarly, in 2 patients with malignant infiltration of lymph nodes, administration of [6,6-(2)H(2)]-glucose (by intravenous infusion for 24 h) before excision biopsy allowed estimation of DNA and RNA turnover in lymph node samples. CONCLUSIONS: Our study results demonstrate the proof-of-principle that deuterium-labeled glucose may be used to analyze RNA turnover, in addition to DNA production/cell proliferation, in clinical samples.
Assuntos
Glucose , Linfonodos/metabolismo , Linfócitos/metabolismo , RNA Ribossômico/metabolismo , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/patologia , Adenosina/metabolismo , Linhagem Celular Tumoral , Proliferação de Células , Deutério , Cromatografia Gasosa-Espectrometria de Massas , Glucose/farmacocinética , Humanos , Leucemia Linfocítica Crônica de Células B/sangue , Linfonodos/patologia , Linfoma não Hodgkin/sangue , Linfoma não Hodgkin/patologia , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Ribonucleosídeos/metabolismo , Sarcoma de Kaposi/sangue , Sarcoma de Kaposi/patologiaRESUMO
Preliminary evidence suggested that human herpesvirus-6 (HHV-6) may act as a cofactor in acquired immunodeficiency syndrome (AIDS) and may contribute to the pathogenesis of lymphoproliferative disorders occurring in individuals infected with the human immunodeficiency virus (HIV). To understand better the biological and clinical significance of HHV-6 infection in the context of HIV-related immunosuppression, the polymerase chain reaction was used to study the frequency and variant distribution of HHV-6 in peripheral blood mononucleated cells (PBMCs) from HIV-seropositive individuals, either asymptomatic or with lymphadenopathy syndrome (LAS) or with overt AIDS. Non-neoplastic and malignant lymphoproliferative disorders from both HIV-infected and HIV-seronegative patients were also investigated using the same series of samples for the presence of Epstein-Barr virus (EBV). When compared with healthy blood donors (12/42, 29%), HHV-6 prevalence in PBMCs showed a progressive decline in HIV-seropositive individuals with asymptomatic HIV infection (3/26, 11%) and in patients with LAS (1/13, 8%) and a significant reduction in patients with overt AIDS (1/20, 20%; P = 0.02). The decrease correlated with the number of CD4+ cells at the time of examination. In addition, HHV-6 DNA sequences were significantly more prevalent in LAS biopsies (13/20, 65%) than in HIV-unrelated reactive lymphadenopathies (2/10, 20%; P = 0.02) and the presence of HHV-6 sequences correlated closely with a histologic pattern of follicular hyperplasia (13/16, 81%; P = 0.003). Strikingly, HHV-6 prevalence decreased in PBMCs of LAS patients, suggesting that the likelihood of interactions between HHV-6 and HIV varies in different body districts. In particular, the demonstration that all HHV-6-carrying LAS samples were also positive for HIV infection suggests that LAS lymph nodes constitute one of the sites where biologically relevant interactions between the two viruses might occur. Also, the prevalence of EBV was higher in LAS (14/20, 70%) than in non-neoplastic lymph nodes from HIV-seronegative individuals (4/10, 40%), although the difference was not statistically significant. EBV was associated strongly with HIV-related malignant lymphoproliferative disorders, being detected in 100% of patients with Hodgkin's disease (HD) and 53% of B-cell non-Hodgkin's lymphomas (NHL). In contrast, the prevalence of HHV-6 DNA in HD and B-cell NHL arisen in HIV-infected patients (30% and 6% respectively) was remarkably lower and similar to that observed in lymphoproliferative disorders from HIV-seronegative patients. Finally, as observed in healthy individuals, HHV-6 variant B was more prevalent than variant A in benign and malignant lymphoproliferative disorders from bot HIV-infected and HIV-seronegative patients. These results suggest that the interactions between HHV-6 and HIV could be different in the various phases of HIV disease and in different districts; HHV-6 has probably no direct role in the pathogenesis of HIV-associated B-cell NHL and HD cases, and behave differently from EBV; and HIV-related immunosuppression does not alter the distribution of HHV-6 variants in these tissues, as observed in the case of EBV.
Assuntos
Complexo Relacionado com a AIDS/virologia , Infecções Oportunistas Relacionadas com a AIDS/virologia , Infecções por Herpesviridae/virologia , Herpesvirus Humano 6/isolamento & purificação , Transtornos Linfoproliferativos/virologia , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/patologia , Infecções Oportunistas Relacionadas com a AIDS/sangue , Infecções Oportunistas Relacionadas com a AIDS/complicações , DNA Viral/sangue , Infecções por HIV/sangue , Infecções por HIV/complicações , Infecções por HIV/virologia , Infecções por Herpesviridae/sangue , Infecções por Herpesviridae/complicações , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/isolamento & purificação , Herpesvirus Humano 6/genética , Humanos , Transtornos Linfoproliferativos/sangue , Transtornos Linfoproliferativos/patologia , Reação em Cadeia da PolimeraseRESUMO
OBJECTIVE: To evaluate the efficacy of 3TC (lamivudine), a synthetic nucleoside analogue that inhibits HIV reverse transcriptase in vitro, as treatment for HIV-positive, asymptomatic or mild AIDS-related complex patients. DESIGN: Open-label, multinational and multicentre, non-comparative, escalating dose study. METHODS: Patients who meet the selection criteria (n = 104) were enrolled in three European countries. Ten to 15 patients were included at each of the six dose levels of 3TC (0.5, 1.0, 2.0, 4.0, 8.0, 12.0 and 20.0 mg/kg daily in two divided doses every 12 h). Virological parameters--immune-complex dissociation (ICD) assay for HIV p24 antigenaemia, plasma HIV RNA load, whole blood assay and cellular viraemia--were evaluated at weeks 0, 4, 12 and 24. RESULTS: Sustained reductions in HIV RNA load and in ICD p24 antigen levels were observed and maintained over the 12-week assessment period. Greater reductions were noted at higher doses but this trend did not reach statistical significance. In 38 patients, reductions of cell viraemia were significantly greater at 4 weeks for patients treated at higher doses of 3TC. CONCLUSION: These virological data show that 3TC is a potent inhibitor of HIV replication in HIV-positive, asymptomatic or mild ARC patients as assessed by ICD p24 antigenaemia, plasma HIV RNA load and cell viraemia.
Assuntos
Antivirais/uso terapêutico , Infecções por HIV/tratamento farmacológico , Inibidores da Transcriptase Reversa/uso terapêutico , Zalcitabina/análogos & derivados , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/tratamento farmacológico , Adulto , Complexo Antígeno-Anticorpo/sangue , Relação Dose-Resposta a Droga , HIV/efeitos dos fármacos , Proteína do Núcleo p24 do HIV/imunologia , Infecções por HIV/sangue , Soropositividade para HIV/sangue , Soropositividade para HIV/tratamento farmacológico , Humanos , Lamivudina , Leucócitos Mononucleares/virologia , Masculino , Reação em Cadeia da Polimerase , Viremia , Zalcitabina/uso terapêuticoRESUMO
In untreated, asymptomatic human immunodeficiency virus type 1 (HIV-1) infection, elevated serum concentrations of soluble receptors for tumor necrosis factor (sTNFR) types I and II are associated with progression to AIDS. To assess the utility of sTNFRs as markers for the assessment of antiretroviral treatment, sTNFRs were sequentially determined in 47 asymptomatic HIV-1-infected men, who participated in a double-blind, randomized, placebo-controlled study. Progression to AIDS or severe AIDS-related complex occurred in six zidovudine (ZDV)- and six placebo-treated subjects. During ZDV treatment (n = 28) both types of sTNFRs declined compared with baseline and placebo, whereas they increased during placebo treatment (n = 19). A sustained decline of sTNFRs occurred only in subjects who experienced no disease progression. During the first 3 months of ZDV treatment, the hazard ratio for disease progression when sTNFR type II rose above the baseline value plus 5% was significantly increased (hazard ratio: approximately 25; 95% confidence interval: approximately 1.5-400; p < 0.03). Simultaneously determined CD4+ counts and serum neopterin levels showed a similar pattern in progressors and nonprogressors. Thus, in contrast to CD4+ counts and neopterin levels, sTNFR concentrations, especially those of the type II STNFR, appear to be valuable surrogate markers for monitoring the efficacy of ZDV treatment in asymptomatic HIV-1 infection.
Assuntos
Antivirais/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1 , Receptores do Fator de Necrose Tumoral/análise , Zidovudina/uso terapêutico , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/tratamento farmacológico , Complexo Relacionado com a AIDS/fisiopatologia , Síndrome da Imunodeficiência Adquirida/sangue , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/fisiopatologia , Adulto , Biomarcadores/análise , Biopterinas/análogos & derivados , Biopterinas/sangue , Contagem de Linfócito CD4 , Progressão da Doença , Método Duplo-Cego , Seguimentos , Proteína do Núcleo p24 do HIV/análise , Infecções por HIV/sangue , Infecções por HIV/fisiopatologia , Humanos , Masculino , Neopterina , Receptores do Fator de Necrose Tumoral/química , SolubilidadeAssuntos
Complexo AIDS Demência/sangue , Infecções por HIV/sangue , Infecções por HIV/psicologia , Fator de Necrose Tumoral alfa/análise , Complexo AIDS Demência/psicologia , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/psicologia , Adolescente , Adulto , Pesquisa em Enfermagem Clínica , Humanos , Testes NeuropsicológicosRESUMO
Between 1984 and 1990, virus was routinely isolated and serum collected from patients diagnosed at hospitals in the Western Cape as suffering from AIDS or AIDS-related conditions (ARC). From these, 17 virus strains were selected at random for sequencing and molecular characterisation of the env gene. The strains were previously characterised as belonging to HIV-1 subtypes B, C and D. The purpose of the present study was to evaluate retrospectively the serological diagnosis of HIV-1 in these 17 South African patients. Thirteen anti-HIV screening assays, including 7 rapid/simple test devices (RTDs), 4 enzyme-linked immunosorbent assays (EIAs) and 2 Western immunoblot assays were evaluated. Using commercial EIAs, 16 serum samples were HIV antibody-positive and these results were confirmed by Western immunoblot analysis. Serum from one terminal AIDS patient was found negative with all the serological tests. Some RTDs gave false negative antibody reactions on specimens from patients infected with subtype D strains. To investigate the false negative antibody reactions, the polymerase chain reaction (PCR) was used to amplify, clone and sequence proviral DNA from the immunodominant gp41 region from 7 of the HIV-1 strains. Two patients, both subtype D strains (D214 and D482) with false negative results in the RTDs, showed a significant amino acid substitution, i.e., substitution of a histidine residue for leucine at env position 607. It was concluded that although there were false negative RTD reactions on patients with HIV-1 subtype D strains, the commercial EIAs tested are sensitive and are able to detect patients infected with HIV-1 subtypes B, C and D that are present in South Africa.
Assuntos
Anticorpos Anti-HIV/sangue , Infecções por HIV/diagnóstico , HIV-1/imunologia , Kit de Reagentes para Diagnóstico , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/diagnóstico , Complexo Relacionado com a AIDS/epidemiologia , Síndrome da Imunodeficiência Adquirida/sangue , Síndrome da Imunodeficiência Adquirida/diagnóstico , Síndrome da Imunodeficiência Adquirida/epidemiologia , Sequência de Bases , Western Blotting/métodos , Estudos de Avaliação como Assunto , Variação Genética , Proteína gp41 do Envelope de HIV/genética , Infecções por HIV/sangue , Infecções por HIV/epidemiologia , HIV-1/classificação , HIV-1/genética , Humanos , Imunoensaio/métodos , Técnicas Imunoenzimáticas , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Reprodutibilidade dos Testes , África do Sul/epidemiologia , Especificidade da EspécieAssuntos
Síndrome da Imunodeficiência Adquirida/terapia , Infecções por HIV/terapia , Imunoterapia Adotiva , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/terapia , Síndrome da Imunodeficiência Adquirida/sangue , Síndrome da Imunodeficiência Adquirida/imunologia , HIV/isolamento & purificação , Proteína do Núcleo p24 do HIV/sangue , Infecções por HIV/sangue , Infecções por HIV/imunologia , Soropositividade para HIV/sangue , Soropositividade para HIV/terapia , Humanos , Reação em Cadeia da Polimerase/métodosRESUMO
Neutrophils from asymptomatic HIV-infected patients have an increased Nitroblue tetrazolium (NBT) reduction, that is an increased production of oxygen radicals. Plasma from these patients can activate normal neutrophils to an increased NBT-reduction and the neutrophil activating factor thus seems to be mainly plasma bound. Further, the patients also have increased levels of plasma malondialdehyde and thus an increased lipid peroxidation. Plasma cysteine levels are low, a sign of increased consumption of antioxidants. Treatment of the asymptomatic HIV-infected patients with N-acetylcysteine corrected the plasma cysteine levels and had some beneficial effects, but did not inhibit the increased radical production by the neutrophils.
Assuntos
Acetilcisteína/uso terapêutico , Infecções por HIV/sangue , Neutrófilos/metabolismo , Superóxidos/sangue , Complexo Relacionado com a AIDS/sangue , Síndrome da Imunodeficiência Adquirida/sangue , Adulto , Cisteína/sangue , Feminino , Radicais Livres , Infecções por HIV/tratamento farmacológico , Humanos , Masculino , Oxirredução , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Selective tropism of human immunodeficiency virus (HIV) for cells with CD4 receptors and especially for TH lymphocytes--key cells in hematopoiesis--has from the clinico-biologic point of view a great many hematologic manifestations of which knowledge is essential for a good diagnosis and treatment as well as for a judicious estimation of prognosis. Thus the study presents the hematologic entities specifically associated with HIV infection (such as ITP, NHML) as well as the hematologic entities associated with HIV infection without presenting a causal relationship with the latter. The study also discusses the quantitative and morphologic changes of peripheral blood and of bone marrow often enlightening for the disease and its complications. An important chapter in the study is devoted to the hematologic changes induced by the HIV infection therapy as well as by the manners of therapeutic approach to the complex hematologic problems raised by the disease.
Assuntos
Infecções por HIV/complicações , HIV-1 , Doenças Hematológicas/etiologia , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/complicações , Complexo Relacionado com a AIDS/diagnóstico , Síndrome da Imunodeficiência Adquirida/sangue , Síndrome da Imunodeficiência Adquirida/complicações , Síndrome da Imunodeficiência Adquirida/diagnóstico , Infecções por HIV/sangue , Infecções por HIV/diagnóstico , Doenças Hematológicas/sangue , Doenças Hematológicas/diagnóstico , Humanos , Linfoma Relacionado a AIDS/sangue , Linfoma Relacionado a AIDS/diagnóstico , Linfoma Relacionado a AIDS/etiologiaRESUMO
Expression of tumor necrosis factor alpha (TNF alpha), interleukin 1 beta (IL-1 beta), and interleukin 6 (IL-6) was evaluated in unstimulated peripheral blood monocytes obtained from human immunodeficiency virus-positive (HIV+) individuals using a reverse transcription-polymerase chain reaction (RT-PCR) method. In all, 40 subjects were included--13 asymptomatic, 11 with ARC, seven with AIDS, and nine HIV- controls. Of the asymptomatic individuals, 85% were positive for TNF alpha and IL-1 beta compared with only 27% of the ARC and 42% of the AIDS patients. Expression of IL-6 message was observed in lesser proportions, with no significant differences among disease states. Quantitation of IL-1 beta and TNF alpha mRNA from the positive samples fell into two categories, low responders (six of 17), with < 5,000 copies of IL-1 beta and TNF alpha mRNA, and high responders (11 of 17), with > 5,000 copies per 10 pg of total cellular RNA. There was no correlation of mRNA detection or concentration with CD4+ cell number or beta 2-microglobulin levels. However, the levels of mRNA, but not its presence alone, were positively correlated with neopterin levels. The data show differential cytokine regulation in monocytes, observed as an increase in the expression of TNF alpha and IL-1 beta compared with IL-6 in HIV+ patients. Our report also emphasizes the utility of an RT-PCR system in analyzing multiple cytokine transcript levels in small amounts of clinical materials.
Assuntos
Regulação da Expressão Gênica , Infecções por HIV/imunologia , Interleucina-1/biossíntese , Interleucina-6/biossíntese , Monócitos/imunologia , Fator de Necrose Tumoral alfa/biossíntese , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/imunologia , Síndrome da Imunodeficiência Adquirida/sangue , Síndrome da Imunodeficiência Adquirida/imunologia , Relação CD4-CD8 , Infecções por HIV/sangue , Soropositividade para HIV/sangue , Soropositividade para HIV/imunologia , Humanos , Interleucina-1/genética , Interleucina-6/genética , Reação em Cadeia da Polimerase , RNA Mensageiro/análise , Análise de Regressão , Transcrição Gênica , Fator de Necrose Tumoral alfa/genéticaRESUMO
IgA antibodies were analysed in sera and saliva from 40 HIV-1 seropositive individuals. The level of total IgA in serum was elevated according to the progress of the disease. IgA antibodies against p24 and gp160 were detected in the asymptomatic phase of infection. However, they declined in the symptomatic phases in contrast with IgG antibodies. Interestingly, three patients in the symptomatic phase who showed high levels of IgA antibodies were all in relatively good clinical condition. The IgG and IgA antibodies in saliva declined in the symptomatic phase. The level of IgG anti-p24 antibodies in saliva correlated with that in serum, suggesting that IgG anti-p24 antibodies in saliva originated from those in the serum. These results indicate that IgA antibodies are regulated independently from IgG antibodies and that the mucosal immune system is impaired early in the symptomatic phase of HIV infection, which starts with mucosal impairment. Detection of IgA antibodies may be useful for prognosis of the disease in HIV-infected individuals. The results indicate also that treatment for the impaired IgA mucosal immune system should be taken into consideration.
Assuntos
Soropositividade para HIV/imunologia , HIV-1/imunologia , Imunoglobulina A/imunologia , Saliva/imunologia , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/imunologia , Síndrome da Imunodeficiência Adquirida/sangue , Síndrome da Imunodeficiência Adquirida/imunologia , Western Blotting , Produtos do Gene env/imunologia , Anticorpos Anti-HIV/imunologia , Proteína do Núcleo p24 do HIV/imunologia , Proteína gp160 do Envelope de HIV , Soropositividade para HIV/sangue , Humanos , Imunoglobulina G/imunologia , Imunoglobulina M/imunologia , Precursores de Proteínas/imunologiaRESUMO
Sera from 871 AIDS and AIDS related complex patients were used to evaluate four ELISA and one agglutination assays. Commercial tests compared were Abbot, Wellcoyzyme, Biotest, Du Pont and Serodia. Wellcozyme and Serodia had the highest sensitivity (96.8 pc and 98.8 pc respectively) but the lowest specificity (53.3 pc and 46.5 pc respectively). Du Pont was the least sensitive test (89.1pc). Biotest and Abbot were comparable--Biotest had a higher sensitivity (93.2pc as compared with 90.6pc) but Abbot had a higher specificity (94.1 pc as compared with 89.1 pc). Thus, Abbott and Biotest both had a satisfactory high sensitivity and specificity and could thereby be recommended for use in screening of HIV-1 antibodies in south east Africa.
Assuntos
Complexo Relacionado com a AIDS/sangue , Síndrome da Imunodeficiência Adquirida/sangue , Testes de Aglutinação/normas , Ensaio de Imunoadsorção Enzimática/métodos , Ensaio de Imunoadsorção Enzimática/normas , Anticorpos Anti-HIV/sangue , HIV-1 , HIV-2 , Complexo Relacionado com a AIDS/epidemiologia , Complexo Relacionado com a AIDS/prevenção & controle , Síndrome da Imunodeficiência Adquirida/epidemiologia , Síndrome da Imunodeficiência Adquirida/prevenção & controle , Western Blotting , Estudos de Avaliação como Assunto , Humanos , Programas de Rastreamento/métodos , Sensibilidade e Especificidade , Zimbábue/epidemiologiaRESUMO
A pilot study was initiated to explore a sequential combination antiretroviral regimen in 21 patients with AIDS or advanced human immunodeficiency virus (HIV) infection, who had received little or no prior anti-HIV therapy. The mean entry CD4 cell count was 184/mm3. Patients received 3-week cycles consisting of zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine for 1 week each. Overall, the regimen was well tolerated for up to 3 years. The principal toxicities were anemia, nausea, and vomiting; 1 patient developed retinal lesions. The mean CD4 cell count reached a peak of 64 cells/mm3 above baseline at week 8 (P = .005 compared to baseline) and remained above baseline for > 40 weeks. Patients also gained weight and had decreases in serum HIV p24 antigen. Eight patients developed opportunistic infections or tumors. Only 4 patients died during 3 years of follow-up. This regimen appears to be generally tolerable and to have anti-HIV activity. Additional studies will be needed, however, to learn how to best combine the available agents in patients with HIV infection.
Assuntos
Complexo Relacionado com a AIDS/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Aciclovir/uso terapêutico , Didanosina/uso terapêutico , Zalcitabina/uso terapêutico , Zidovudina/uso terapêutico , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/imunologia , Síndrome da Imunodeficiência Adquirida/sangue , Síndrome da Imunodeficiência Adquirida/imunologia , Aciclovir/administração & dosagem , Adulto , Antígenos CD/sangue , Biomarcadores/sangue , Peso Corporal , Antígenos CD4/sangue , Didanosina/administração & dosagem , Esquema de Medicação , Quimioterapia Combinada , Proteína do Núcleo p24 do HIV/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Subpopulações de Linfócitos T/imunologia , Fatores de Tempo , Zalcitabina/administração & dosagem , Zidovudina/administração & dosagemRESUMO
We evaluated the prognostic role of a novel tumour-associated antigen, termed 90K, in a cohort of HIV+ asymptomatic haemophilia patients with known duration of seropositivity and median follow-up of about 7 years. The circulating levels of 90K are higher in HIV+ asymptomatic patients than HIV- controls. The antigen levels remain quite stable over time in non-progressing patients, while they steadily rise in patients evolving to ARC/AIDS. Baseline high 90K levels are predictive of faster progression to ARC/AIDS and shorter survival. We conclude that an elevated 90K serum level is a predictor of poor prognosis in HIV+ asymptomatic haemophiliacs.
Assuntos
Antígenos de Neoplasias/sangue , Infecções por HIV/sangue , Hemofilia A/complicações , Lipoproteínas , Proteínas de Neoplasias , Complexo Relacionado com a AIDS/sangue , Síndrome da Imunodeficiência Adquirida/sangue , Adolescente , Adulto , Idoso , Biomarcadores/sangue , Biomarcadores Tumorais , Proteínas de Transporte , Criança , Pré-Escolar , Seguimentos , Glicoproteínas , Infecções por HIV/complicações , Humanos , Masculino , Pessoa de Meia-Idade , PrognósticoRESUMO
OBJECTIVE: To assess the efficacy and the mechanism of action of alpha-interferon (alpha-IFN) in the treatment of HIV-related thrombocytopenia. METHODS: Thirteen HIV-positive subjects [nine men and four women with severe thrombocytopenia (platelets, < or = 30 x 10(9)/l)] were treated with alpha-IFN 2b alone at a dose of 3 x 10(6) U three times a week for 5 weeks. Haematological parameters, platelet kinetic and bone-marrow myeloid progenitor cultures [megakaryocyte colony-forming units (CFU-MK); granulocyte macrophage CFU (CFU-GM) and erythroid burst-forming units (BFU-E)] were evaluated before and after treatment in responsive subjects. RESULTS: Seven out of 13 subjects showed a partial response (platelets, 50-149 x 10(9)/l) after alpha-IFN 2b therapy. Platelet survival as evaluated by 111In-oxine significantly increased, while platelet turnover showed a slight but not statistically significant increase after treatment. The growth of bone-marrow myeloid progenitor cells decreased after alpha-IFN 2b therapy, again without statistical significance. CONCLUSION: alpha-IFN 2b may increase the platelet count in HIV-positive subjects with severe symptomatic thrombocytopenia by prolonging platelet survival. The immunomodulatory and antiviral action of this drug may be responsible for prolonged platelet survival.
Assuntos
Complexo Relacionado com a AIDS/complicações , Interferon-alfa/uso terapêutico , Trombocitopenia/terapia , Complexo Relacionado com a AIDS/sangue , Adulto , Doenças Autoimunes/sangue , Doenças Autoimunes/complicações , Doenças Autoimunes/terapia , Sobrevivência Celular , Células Cultivadas , Ensaio de Unidades Formadoras de Colônias , Avaliação de Medicamentos , Células Precursoras Eritroides/efeitos dos fármacos , Células Precursoras Eritroides/patologia , Eritropoetina/farmacologia , Feminino , Fator Estimulador de Colônias de Granulócitos e Macrófagos/farmacologia , Hematopoese/efeitos dos fármacos , Humanos , Interferon alfa-2 , Interleucina-3/farmacologia , Masculino , Megacariócitos/efeitos dos fármacos , Megacariócitos/patologia , Contagem de Plaquetas/efeitos dos fármacos , Púrpura Trombocitopênica Idiopática/sangue , Púrpura Trombocitopênica Idiopática/complicações , Púrpura Trombocitopênica Idiopática/terapia , Proteínas Recombinantes/farmacologia , Trombocitopenia/sangue , Trombocitopenia/complicações , Trombocitopenia/patologiaRESUMO
Granulocytopenia is a complication of human immunodeficiency virus disease, as well as a toxic manifestation of zidovudine therapy. To evaluate pharmacokinetic and pharmacodynamic relationships, 11 AIDS-AIDS-related complex patients who had developed zidovudine-associated granulocytopenia (mean absolute neutrophil count, 1,077/mm3) were examined after addition of granulocyte-macrophage colony-stimulating factor (GM-CSF) to zidovudine. GM-CSF was administered as a daily (1.0 or 0.3 micrograms/kg) or every-other-day (0.3 micrograms/kg) subcutaneous dose over a 28-day period. Zidovudine was continued at the same daily dosage as was previously being administered. Of 11 patients, 7 (1.0 micrograms/kg, n = 5; 0.3 micrograms/kg, n = 2) had a pharmacologic response to GM-CSF with an increase to a mean absolute neutrophil count of 3,189 cells per mm3 at 4 weeks (P < 0.05). The peak concentration of GM-CSF in plasma ranged from 11.5 to 84.4 pg/ml, and the time to peak ranged from 1 to 3 h. No correlation between GM-CSF disposition and hematologic response was noted. A decreased plasma zidovudine-glucuronide/zidovudine ratio was noted after 1 week of GM-CSF, and an increase in the area under the plasma concentration-versus-time curve for zidovudine was found in three patients after 4 weeks. Low doses of GM-CSF can raise the granulocyte count in patients with zidovudine-induced neutropenia. The use of GM-CSF and zidovudine may represent a viable treatment option for persons with human immunodeficiency virus infection who develop neutropenia while receiving zidovudine but do not tolerate alternative nucleoside analogs. Further studies are needed to assess the complex interaction between these two agents.
Assuntos
Complexo Relacionado com a AIDS/sangue , Síndrome da Imunodeficiência Adquirida/sangue , Fator Estimulador de Colônias de Granulócitos e Macrófagos/farmacologia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/farmacocinética , Zidovudina/farmacologia , Zidovudina/farmacocinética , Complexo Relacionado com a AIDS/tratamento farmacológico , Complexo Relacionado com a AIDS/microbiologia , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/microbiologia , Administração Oral , Adulto , Esquema de Medicação , Feminino , Fator Estimulador de Colônias de Granulócitos e Macrófagos/efeitos adversos , HIV-1/efeitos dos fármacos , Humanos , Injeções Subcutâneas , Contagem de Leucócitos/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Neutrófilos/efeitos dos fármacos , Zidovudina/efeitos adversosRESUMO
OBJECTIVE: To evaluate the efficacy and safety of zidovudine (ZDV) at a maintenance dose of 250 mg every 6 h alone or as cotherapy with acyclovir (ACV; 800 mg every 6 h) as treatment for AIDS and AIDS-related complex (ARC). DESIGN: Double-blind, randomized, placebo-controlled clinical trial of up to 1 year's therapy. SETTING: Teaching hospital ambulatory clinics in eight European countries and Australia. SUBJECTS: A total of 131 patients with AIDS and 134 with ARC were enrolled and followed from 1986 to 1988. MAIN OUTCOME MEASURES: Time to development of AIDS-defining opportunistic infections and AIDS-associated neoplasms, survival assessed at 1 year after entry, performance status, body weight, CD4+ cell counts. RESULTS: During the study period, 46 (36%) ZDV recipients and 37 (27%) cotherapy recipients developed opportunistic infections. The probability of an ARC patient progressing to AIDS (1982 Centers for Disease Control criteria) was 0.18 and 0.15 [95% confidence interval (CI) for difference, -0.17 to 0.11] for the ZDV alone and cotherapy recipients, respectively. After excluding patients who experienced an opportunistic infection during the first 4 weeks of therapy, the probability was 0.13 and 0.099 (95% CI for difference, -0.16 to 0.10) for the ZDV and cotherapy recipients, respectively. Thirty-six patients treated with single-agent therapy [28 (41%) AIDS and eight (12%) ARC patients] and 15 cotherapy recipients [13 (21%) AIDS and two (3%) ARC patients] died during the study. There was a significant difference in time to death between the cotherapy and ZDV alone groups for both AIDS (P = 0.014) and ARC (P = 0.045) patients, with cotherapy patients surviving longer. Infections related to herpesviruses, but not cytomegalovirus, were reduced in patients receiving ACV therapy. CD4+ cell counts in both arms generally increased initially and then declined. Forty-six per cent of patients in the ZDV group (59% of AIDS and 31% of ARC patients) and 52% of patients in the cotherapy group (69% of AIDS and 34% of ARC patients) experienced bone-marrow suppression. Red cell transfusions were administered to 33% of ZDV alone recipients and 34% of cotherapy recipients. CONCLUSION: These data show that the addition of high-dose ACV cotherapy to ZDV for patients with AIDS and advanced ARC results in a statistically significant improvement in survival with minimal increase in the risk of toxicity.
Assuntos
Complexo Relacionado com a AIDS/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Aciclovir/uso terapêutico , Zidovudina/uso terapêutico , Complexo Relacionado com a AIDS/sangue , Complexo Relacionado com a AIDS/complicações , Infecções Oportunistas Relacionadas com a AIDS/prevenção & controle , Síndrome da Imunodeficiência Adquirida/sangue , Síndrome da Imunodeficiência Adquirida/complicações , Aciclovir/administração & dosagem , Adulto , Linfócitos T CD4-Positivos , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Humanos , Contagem de Leucócitos , Masculino , Segurança , Zidovudina/administração & dosagem , Zidovudina/efeitos adversosRESUMO
A case of Cushing's syndrome in a 24-yr-old homosexual with an AIDS-related complex is reported. In this patient certain symptoms common to both diseases, i.e. weakness, myalgia and muscle atrophy were accentuated, whereas other symptoms pathognomic of the human immunodeficiency virus (HIV) infection, i.e. lymphoadenopathies and weight loss, were less pronounced by the high levels of circulating adrenal steroids. Ketoconazole was administered po in order to block adrenal steroidogenesis, the drug caused a remarkable fall of cortisol serum concentrations, but was unable to modify significantly the immunological pattern of the patient. Our data suggest that changes of serum adrenal steroid levels have little effect on the immune network of patients with AIDS.
Assuntos
Complexo Relacionado com a AIDS/sangue , Corticosteroides/sangue , Síndrome de Cushing/sangue , Complexo Relacionado com a AIDS/tratamento farmacológico , Complexo Relacionado com a AIDS/imunologia , Corticosteroides/urina , Neoplasias das Glândulas Suprarrenais/diagnóstico por imagem , Neoplasias das Glândulas Suprarrenais/fisiopatologia , Adulto , Síndrome de Cushing/tratamento farmacológico , Síndrome de Cushing/imunologia , Humanos , Cetoconazol/uso terapêutico , Masculino , RadiografiaRESUMO
Myelosuppression is associated with human immunodeficiency virus (HIV) infection and may also be produced by agents used for the treatment of the disease or the treatment of its complications. Didanosine (ddl; 2',3'-dideoxyinosine) is a newer purine nucleoside that has recently become available for therapy for HIV infection. The effects of didanosine on peripheral blood counts have been retrospectively evaluated in the first 170 patients treated with this new agent in four phase I trials. Patients treated with didanosine showed statistically significant improvements in hemoglobin levels, white cell counts, and granulocyte and platelet numbers as compared with baseline values. These changes were seen with or without prior therapy with zidovudine, were somewhat more pronounced at higher doses of didanosine, and persisted for up to 1 year. Reported adverse events included peripheral neuropathy, diarrhea, and most notably, pancreatitis. It is concluded that, while some toxic side effects occur, didanosine therapy in HIV infection is associated with an amelioration of HIV-induced myelosuppression.